These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29097939)

  • 1. Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with
    Tolmachev V; Yim CB; Rajander J; Perols A; Karlström AE; Haaparanta-Solin M; Grönroos TJ; Solin O; Orlova A
    Contrast Media Mol Imaging; 2017; 2017():8565802. PubMed ID: 29097939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
    Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.
    Strand J; Honarvar H; Perols A; Orlova A; Selvaraju RK; Karlström AE; Tolmachev V
    PLoS One; 2013; 8(8):e70028. PubMed ID: 23936372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
    Altai M; Strand J; Rosik D; Selvaraju RK; Eriksson Karlström A; Orlova A; Tolmachev V
    Bioconjug Chem; 2013 Jun; 24(6):1102-9. PubMed ID: 23705574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
    Altai M; Perols A; Karlström AE; Sandström M; Boschetti F; Orlova A; Tolmachev V
    Nucl Med Biol; 2012 May; 39(4):518-29. PubMed ID: 22172396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of
    Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
    Qi S; Hoppmann S; Xu Y; Cheng Z
    Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
    Honarvar H; Jokilaakso N; Andersson K; Malmberg J; Rosik D; Orlova A; Karlström AE; Tolmachev V; Järver P
    Nucl Med Biol; 2013 Apr; 40(3):378-86. PubMed ID: 23357083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates.
    Honarvar H; Strand J; Perols A; Orlova A; Selvaraju RK; Eriksson Karlström A; Tolmachev V
    Mol Imaging; 2014; 13():. PubMed ID: 25249017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
    Beaino W; Anderson CJ
    J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
    Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
    Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
    Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
    Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
    Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
    Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
    Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
    Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
    Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
    Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.